A Case of Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab
-
- Unome Shinji
- Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan
-
- Imai Kenji
- Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan
-
- Miwa Takao
- Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan
-
- Hanai Tatsunori
- Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan
-
- Suetsugu Atsushi
- Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan
-
- Takai Koji
- Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan
-
- Suzui Natsuko
- Department of Pathology, Gifu University, Japan
-
- Miyazaki Tatsuhiko
- Department of Pathology, Gifu University, Japan
-
- Shimizu Masahito
- Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan
Abstract
<p>Combined hepatocellular cholangiocarcinoma is a rare and challenging primary liver malignancy that lacks any established standard treatments for unresectable cases. We herein present the first known case of a 49-year-old woman diagnosed with unresectable combined hepatocellular-cholangiocarcinoma, who underwent novel chemotherapy involving durvalumab plus tremelimumab combination therapy. The treatment was temporarily discontinued owing to immune-related adverse events, such as rash, and the patient was subsequently managed with systemic steroid therapy; however, the disease progressed after two courses of this treatment. Further studies are needed to validate the efficacy and safety of immune checkpoint inhibitors such as durvalumab and tremelimumab for the treatment of unresectable combined hepatocellular cholangiocarcinoma. </p>
Journal
-
- Internal Medicine
-
Internal Medicine advpub (0), 2024
The Japanese Society of Internal Medicine